241 related articles for article (PubMed ID: 23767932)
1. RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.
Stornaiuolo A; Piovani BM; Bossi S; Zucchelli E; Corna S; Salvatori F; Mavilio F; Bordignon C; Rizzardi GP; Bovolenta C
Hum Gene Ther Methods; 2013 Aug; 24(4):228-40. PubMed ID: 23767932
[TBL] [Abstract][Full Text] [Related]
2. A new-generation stable inducible packaging cell line for lentiviral vectors.
Farson D; Witt R; McGuinness R; Dull T; Kelly M; Song J; Radeke R; Bukovsky A; Consiglio A; Naldini L
Hum Gene Ther; 2001 May; 12(8):981-97. PubMed ID: 11387062
[TBL] [Abstract][Full Text] [Related]
3. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
4. Production of lentiviral vectors for transducing cells from the central nervous system.
Li M; Husic N; Lin Y; Snider BJ
J Vis Exp; 2012 May; (63):e4031. PubMed ID: 22664962
[TBL] [Abstract][Full Text] [Related]
5. RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors.
Bell AJ; Fegen D; Ward M; Bank A
Exp Biol Med (Maywood); 2010 Oct; 235(10):1269-76. PubMed ID: 20876083
[TBL] [Abstract][Full Text] [Related]
6. RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope.
Marin V; Stornaiuolo A; Piovan C; Corna S; Bossi S; Pema M; Giuliani E; Scavullo C; Zucchelli E; Bordignon C; Rizzardi GP; Bovolenta C
Mol Ther Methods Clin Dev; 2016; 3():16033. PubMed ID: 27222840
[TBL] [Abstract][Full Text] [Related]
7. Packaging HIV- or FIV-based lentivector expression constructs and transduction of VSV-G pseudotyped viral particles.
Mendenhall A; Lesnik J; Mukherjee C; Antes T; Sengupta R
J Vis Exp; 2012 Apr; (62):e3171. PubMed ID: 22508377
[TBL] [Abstract][Full Text] [Related]
8. Transduction of human hematopoietic stem cells by lentiviral vectors pseudotyped with the RD114-TR chimeric envelope glycoprotein.
Di Nunzio F; Piovani B; Cosset FL; Mavilio F; Stornaiuolo A
Hum Gene Ther; 2007 Sep; 18(9):811-20. PubMed ID: 17824830
[TBL] [Abstract][Full Text] [Related]
9. Development of Third-generation Cocal Envelope Producer Cell Lines for Robust Lentiviral Gene Transfer into Hematopoietic Stem Cells and T-cells.
Humbert O; Gisch DW; Wohlfahrt ME; Adams AB; Greenberg PD; Schmitt TM; Trobridge GD; Kiem HP
Mol Ther; 2016 Aug; 24(7):1237-46. PubMed ID: 27058824
[TBL] [Abstract][Full Text] [Related]
10. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors.
Wagner R; Graf M; Bieler K; Wolf H; Grunwald T; Foley P; Uberla K
Hum Gene Ther; 2000 Nov; 11(17):2403-13. PubMed ID: 11096444
[TBL] [Abstract][Full Text] [Related]
11. Lentiviral vector transduction of a dominant-negative Rev gene into human CD34+ hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication.
Bahner I; Sumiyoshi T; Kagoda M; Swartout R; Peterson D; Pepper K; Dorey F; Reiser J; Kohn DB
Mol Ther; 2007 Jan; 15(1):76-85. PubMed ID: 17164778
[TBL] [Abstract][Full Text] [Related]
12. Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines.
Manceur AP; Kim H; Misic V; Andreev N; Dorion-Thibaudeau J; Lanthier S; Bernier A; Tremblay S; Gélinas AM; Broussau S; Gilbert R; Ansorge S
Hum Gene Ther Methods; 2017 Dec; 28(6):330-339. PubMed ID: 28826344
[TBL] [Abstract][Full Text] [Related]
13. Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions.
ter Brake O; Berkhout B
J Gene Med; 2007 Sep; 9(9):743-50. PubMed ID: 17628029
[TBL] [Abstract][Full Text] [Related]
14. Helper plasmids for production of HIV-1-derived vectors.
Fuller M; Anson DS
Hum Gene Ther; 2001 Nov; 12(17):2081-93. PubMed ID: 11747598
[TBL] [Abstract][Full Text] [Related]
15. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors.
Sparacio S; Pfeiffer T; Schaal H; Bosch V
Mol Ther; 2001 Apr; 3(4):602-12. PubMed ID: 11319923
[TBL] [Abstract][Full Text] [Related]
16. Abrogated cryptic activation of lentiviral transfer vectors.
Luche RM; Enssle J; Kiem HP
Sci Rep; 2012; 2():438. PubMed ID: 22666541
[TBL] [Abstract][Full Text] [Related]
17. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates.
Sandrin V; Boson B; Salmon P; Gay W; Nègre D; Le Grand R; Trono D; Cosset FL
Blood; 2002 Aug; 100(3):823-32. PubMed ID: 12130492
[TBL] [Abstract][Full Text] [Related]
18. Development of inducible EIAV-based lentiviral vector packaging and producer cell lines.
Stewart HJ; Leroux-Carlucci MA; Sion CJ; Mitrophanous KA; Radcliffe PA
Gene Ther; 2009 Jun; 16(6):805-14. PubMed ID: 19262613
[TBL] [Abstract][Full Text] [Related]
19. Development of an Rev-independent, minimal simian immunodeficiency virus-derived vector system.
Pandya S; Boris-Lawrie K; Leung NJ; Akkina R; Planelles V
Hum Gene Ther; 2001 May; 12(7):847-57. PubMed ID: 11339901
[TBL] [Abstract][Full Text] [Related]
20. Lentiviral vectors for gene therapy of HIV-1 infection.
Mautino MR
Curr Gene Ther; 2002 Feb; 2(1):23-43. PubMed ID: 12108972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
